News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,486 Results
Type
Article (14189)
Company Profile (282)
Press Release (252015)
Section
Business (79497)
Career Advice (153)
Deals (13224)
Drug Delivery (35)
Drug Development (50441)
Employer Resources (31)
FDA (5714)
Job Trends (5127)
News (144376)
Policy (10028)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (910)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21632)
ALS (61)
Alzheimer's disease (824)
Antibody-drug conjugate (ADC) (87)
Approvals (5729)
Artificial intelligence (108)
Autoimmune disease (10)
Automation (5)
Bankruptcy (104)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (40)
Biotechnology (232)
Bladder cancer (44)
Brain cancer (19)
Breast cancer (141)
Cancer (1295)
Cardiovascular disease (106)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (305)
Cervical cancer (8)
Clinical research (40873)
Collaboration (497)
Compensation (219)
Complete response letters (13)
COVID-19 (1034)
CRISPR (36)
C-suite (141)
Cystic fibrosis (76)
Data (1352)
Denatured (11)
Depression (28)
Diabetes (125)
Diagnostics (1292)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (77)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (81)
Earnings (29656)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (48109)
Executive appointments (396)
FDA (6332)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (463)
Gene editing (87)
Generative AI (9)
Gene therapy (228)
GLP-1 (353)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6588)
Huntington's disease (21)
IgA nephropathy (21)
Immunology and inflammation (79)
Indications (18)
Infectious disease (1096)
Inflammatory bowel disease (110)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (55)
Interviews (17)
IPO (7261)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (200)
Leadership (2)
Legal (1386)
Liver cancer (30)
Lung cancer (185)
Lymphoma (82)
Machine learning (1)
Management (7)
Manufacturing (115)
MASH (48)
Medical device (2588)
Medtech (2589)
Mergers & acquisitions (6249)
Metabolic disorders (363)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (57)
Neuropsychiatric disorders (23)
Neuroscience (1190)
NextGen: Class of 2025 (2017)
Non-profit (854)
Northern California (1543)
Now hiring (21)
Obesity (185)
Opinion (100)
Ovarian cancer (60)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (104)
Partnered (8)
Patents (110)
Patient recruitment (66)
Peanut (35)
People (25492)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14428)
Phase II (19018)
Phase III (12024)
Pipeline (704)
Podcasts (46)
Policy (36)
Postmarket research (852)
Preclinical (6061)
Press Release (30)
Prostate cancer (54)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (272)
Real estate (1414)
Recruiting (12)
Regulatory (8559)
Reports (15)
Research institute (936)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (3)
RSV (10)
Schizophrenia (55)
Series A (91)
Series B (59)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1367)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1971)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (33)
United States (12043)
Vaccines (204)
Venture capitalists (28)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (66)
Last 7 days (382)
Last 30 days (1546)
Last 365 days (20036)
2025 (4661)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16223)
2018 (11739)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (38)
Alaska (2)
Arizona (52)
Arkansas (5)
Asia (17217)
Australia (2915)
California (3504)
Canada (1048)
China (322)
Colorado (136)
Connecticut (143)
Delaware (88)
Europe (37017)
Florida (410)
Georgia (107)
Idaho (16)
Illinois (209)
India (8)
Indiana (85)
Iowa (1)
Japan (70)
Kansas (59)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (442)
Massachusetts (2755)
Michigan (69)
Minnesota (135)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (877)
New Mexico (12)
New York (951)
North Carolina (517)
North Dakota (4)
Northern California (1543)
Ohio (107)
Oklahoma (9)
Oregon (21)
Pennsylvania (669)
Puerto Rico (3)
Rhode Island (15)
South America (208)
South Carolina (4)
Southern California (1367)
Tennessee (25)
Texas (402)
Utah (48)
Virginia (67)
Washington D.C. (28)
Washington State (319)
Wisconsin (13)
266,486 Results for "proqr therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ProQR Announces Year End 2024 Operating and Financial Results
March 14, 2025
·
9 min read
Press Releases
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024
December 5, 2024
·
8 min read
Genetown
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massachusetts.
June 18, 2024
·
5 min read
Business
ProQR Announces First Quarter 2024 Operating and Financial Results
ProQR Therapeutics NV. reported its financial and operating results for the first quarter ended March 31, 2024, and provided a business update.
May 9, 2024
·
17 min read
Press Releases
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
December 11, 2024
·
6 min read
Press Releases
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
December 11, 2024
·
7 min read
Press Releases
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
October 7, 2024
·
5 min read
Business
ProQR Announces Year End 2023 Operating and Financial Results
ProQR Therapeutics NV. reported its financial and operating results for the year ended December 31, 2023, and provided a business update.
March 13, 2024
·
13 min read
Policy
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
ProQR Therapeutics N.V. today announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer™.
April 19, 2024
·
5 min read
Genetown
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR) today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.
April 22, 2024
·
5 min read
1 of 26,649
Next
